-
公开(公告)号：US07482322B2
公开(公告)日：2009-01-27
申请号：US10573262
申请日：2004-10-28
申请人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
发明人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
IPC分类号： A61K38/16 , A61K38/00 , C07K14/435 , C07K14/00
CPC分类号： C07K14/705 , A61K38/00
摘要： The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or heterologous polypeptide sequences, antibodies which bind to the polypeptides, methods for producing the polypeptides of the present invention. Conditions that can be diagnosed, screened, prevented, or treated by the compositions herein include prophylactic, angiogenesis and conservation of functions in various organs, angiogenesis at the time of tumor and regeneration of various organs, proliferation, differentiation and preservation of function of the cells in various organs, aging, and dysfunction of the present invention.
摘要翻译： 本发明涉及一种新型的plexin家族如DNA，含有该DNA的基因，由该DNA编码的新型多肽，含有该多肽或异源多肽序列的重组蛋白，与该多肽结合的抗体，产生多肽的多肽的方法 本发明。 可以通过本文组合物诊断，筛选，预防或治疗的病症包括各种器官的功能的预防，血管生成和保护，肿瘤时的血管发生和各种器官的再生，细胞的功能的增殖，分化和保存 在本发明的各种器官，衰老和功能障碍中。
-
公开(公告)号：US20070212365A1
公开(公告)日：2007-09-13
申请号：US10573262
申请日：2004-10-28
申请人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
发明人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
CPC分类号： C07K14/705 , A61K38/00
摘要： The object of the invention is to provide novel DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide, or an antibody against the polypeptide, which is useful for development and screening of prophylactic, therapeutic and diagnostic drug for angiogenesis and conservation of functions in various organs, angiogenesis at the time of tumor and regeneration of various organs, proliferation, differentiation and preservation of function of the cells in various organs, aging, and dysfunction. Means to Solve the Problem A DNA comprising a base sequence encoding one of the following polypeptide (a) or (b): (a) a polypeptide comprising the full length or a part of an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:15 or SEQ ID NO:18, and (b) a polypeptide comprising an amino acid sequence derived from an amino acid sequence represented by SEQ ID NO:1, SEQ ID NO:15 or SEQ ID NO:18 by deletion, substitution or addition of a part of the amino acids and having a biological activity substantially equivalent to the polypeptide (a).
摘要翻译： 本发明的目的是提供新的DNA，含有DNA的基因，由DNA编码的新型多肽，含有多肽的重组蛋白或抗多肽的抗体，其可用于开发和筛选预防性治疗和 用于血管发生的诊断药物和各种器官功能的保存，肿瘤时的血管发生和各种器官的再生，增殖，分化和保存各种器官，衰老和功能障碍中的细胞的功能。 解决问题的方法包含编码以下多肽（a）或（b）之一的碱基序列的DNA：（a）包含相同或基本相同的氨基酸序列的全长或部分的多肽 作为由SEQ ID NO：1，SEQ ID NO：15或SEQ ID NO：18表示的氨基酸序列，和（b）包含源自SEQ ID NO：1所示氨基酸序列的氨基酸序列的多肽， SEQ ID NO：15或SEQ ID NO：18，通过缺失，取代或添加一部分氨基酸并且具有与多肽（a）基本相同的生物活性。
-
公开(公告)号：US20130059375A1
公开(公告)日：2013-03-07
申请号：US13639059
申请日：2011-04-01
IPC分类号： C12N5/0735
CPC分类号： C12N5/0606 , A01K67/0275 , C12N2501/115 , C12N2501/235 , C12N2501/42 , C12N2501/727 , C12N2501/855
摘要： The present invention provides a method of producing a mammalian ES cell, including cultivating a mammalian inner cell mass in a medium containing adrenocorticotropic hormone, an FGF receptor inhibitor, an MEK activation inhibitor and a GSK3 inhibitor, and isolating a mammalian ES cell from the culture.
摘要翻译： 本发明提供一种哺乳动物ES细胞的制备方法，包括在含有促肾上腺皮质激素的培养基，FGF受体抑制剂，MEK活化抑制剂和GSK3抑制剂的培养物中培养哺乳动物内细胞团，并从培养物中分离哺乳动物ES细胞 。
-
4.发明申请公开(公告)号：US20090215170A1
公开(公告)日：2009-08-27
申请号：US12318086
申请日：2008-12-22
申请人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
发明人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
CPC分类号： C07K14/705 , A61K38/00
摘要： The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or heterologous polypeptide sequences, antibodies which bind to the polypeptides, methods for producing the polypeptides of the present invention. Conditions that can be diagnosed, screened, prevented, or treated by the compositions herein include prophylactic, angiogenesis and conservation of functions in various organs, angiogenesis at the time of tumor and regeneration of various organs, proliferation, differentiation and preservation of function of the cells in various organs, aging, and dysfunction of the present invention.
摘要翻译： 本发明涉及一种新型的plexin家族如DNA，含有该DNA的基因，由该DNA编码的新型多肽，含有该多肽或异源多肽序列的重组蛋白，与该多肽结合的抗体，产生多肽的多肽的方法 本发明。 可以通过本文组合物诊断，筛选，预防或治疗的病症包括各种器官的功能的预防，血管生成和保护，肿瘤时的血管发生和各种器官的再生，细胞的功能的增殖，分化和保存 在本发明的各种器官，衰老和功能障碍中。
-
公开(公告)号：US10813950B2
公开(公告)日：2020-10-27
申请号：US13991059
申请日：2011-12-02
IPC分类号： A61K35/17 , C12N5/0783 , C07K14/725 , A61K45/06 , A61K31/7028 , C12N15/85
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
-
6.发明授权Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way 有权从具有T细胞抗原受体α链区域的重编程体细胞产生成熟的NKT细胞，以NKT细胞特异性方式重排为均匀的Va-Ja公开(公告)号：US08945922B2
公开(公告)日：2015-02-03
申请号：US13062453
申请日：2009-09-08
IPC分类号： C12N5/02 , A61K31/7036 , C12N5/0783 , C12N5/074 , A61K35/12
CPC分类号： A61K31/7036 , A61K35/12 , C12N5/0646 , C12N5/0696 , C12N2501/23 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/26 , C12N2501/42 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/11 , C12N2506/45
摘要： Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination.
摘要翻译： 提供衍生自体细胞如NKT细胞的iPS细胞，其具有T细胞抗原受体基因的α链区域以NKT细胞受体特异性方式重排为均匀的Vα-Jα，从iPS分化的NKT细胞 细胞，其制备方法以及使用从iPS细胞分化的细胞制备的免疫细胞治疗剂。 还提供了将具有重排为T细胞抗原受体基因的α-链区域的体细胞例如NKT细胞与NKT-TCR（NKT-iPS细胞）重排的TCRα的iPS细胞重排为均匀的Vα -Jα以NKT细胞受体特异性方式，具有核重编程因子，通过离体iPS细胞（iPS-NKT细胞）分化获得的分离的NKT细胞，产生CD4 / CD8-双重阳性NKT细胞的方法（DP-NKT 细胞）和来自NKT-iPS细胞的成熟NKT细胞，通过改变饲养细胞和/或细胞因子的组合，扩增iPS-NKT细胞的方法和包含用α-半乳糖基神经酰胺（α）活化的NKT细胞的NKT细胞细胞治疗剂 -GalCer）或iPS-NKT细胞和α-GalCer组合。
-
7.发明申请IN VITRO DIFFERENTIATION/INDUCTION OF LYMPHOCYTE FROM STEM CELL HAVING GENOTYPE PROVIDED AFTER GENE RECONSTITUTION 审中-公开在具有基因组重组后提供的基因组的干细胞中进行体外分化/诱导淋巴细胞公开(公告)号：US20110020932A1
公开(公告)日：2011-01-27
申请号：US12442887
申请日：2007-09-21
申请人： Hiroshi Wakao , Shin-ichiro Fujii , Kanako Shimizu , Haruhiko Koseki , Masaru Taniguchi , Atsuo Ogura , Hiroshi Kawamoto
发明人： Hiroshi Wakao , Shin-ichiro Fujii , Kanako Shimizu , Haruhiko Koseki , Masaru Taniguchi , Atsuo Ogura , Hiroshi Kawamoto
IPC分类号： C12N5/10
CPC分类号： C12N5/0646 , C12N2501/23 , C12N2501/42 , C12N2502/1394 , C12N2502/99 , C12N2506/02 , C12N2517/04
摘要： The present invention provides a production method of a functional differentiated cell having a post-rearrangement genotype of a particular antigen receptor gene, which includes culturing a stem cell having the genotype in a medium to give the differentiated cell derived from the stem cell. As the stem cell having the genotype, a stem cell (e.g., ES cell) established by transplantation of the nucleus of a cell having the genotype is preferable. As the differentiated cell, NKT cell is preferable.
摘要翻译： 本发明提供了具有特定抗原受体基因的重排后基因型的功能性分化细胞的制备方法，其包括在培养基中培养具有基因型的干细胞，得到源自干细胞的分化细胞。 作为具有基因型的干细胞，优选通过移植具有基因型的细胞的细胞核建立的干细胞（例如ES细胞）。 作为分化细胞，优选NKT细胞。
-
公开(公告)号：US07816132B2
公开(公告)日：2010-10-19
申请号：US12318086
申请日：2008-12-22
申请人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
发明人： Hisashi Koga , Osamu Ohara , Haruhiko Koseki , Mitsuhiro Okada , Akiyoshi Uemura , Hiroki Arakawa , Mitsuhiro Tada
CPC分类号： C07K14/705 , A61K38/00
摘要： The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or heterologous polypeptide sequences, antibodies which bind to the polypeptides, methods for producing the polypeptides of the present invention. Conditions that can be diagnosed, screened, prevented, or treated by the compositions herein include prophylactic, angiogenesis and conservation of functions in various organs, angiogenesis at the time of tumor and regeneration of various organs, proliferation, differentiation and preservation of function of the cells in various organs, aging, and dysfunction of the present invention.
摘要翻译： 本发明涉及一种新型的plexin家族如DNA，含有该DNA的基因，由该DNA编码的新型多肽，含有该多肽或异源多肽序列的重组蛋白，与该多肽结合的抗体，产生多肽的多肽的方法 本发明。 可以通过本文组合物诊断，筛选，预防或治疗的病症包括各种器官的功能的预防，血管生成和保护，肿瘤时的血管发生和各种器官的再生，细胞的功能的增殖，分化和保存 在本发明的各种器官，衰老和功能障碍中。
-
9.发明申请IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS 审中-公开使用ALLO-NKT细胞的免疫疗法，其中T细胞受体（TCR）基因的免疫应答细胞已经被重新分化为V-ALPHA-J-ALPHA，以及从固体细胞衍生的NKT细胞的储存公开(公告)号：US20130295142A1
公开(公告)日：2013-11-07
申请号：US13991059
申请日：2011-12-02
IPC分类号： A61K35/14 , C12N15/85 , A61K31/7028
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
摘要翻译： 本发明提供了一种用于免疫细胞治疗的药剂，其包含NKT细胞，所述NKT细胞通过体外将具有T细胞受体基因的α链区域的细胞以NKT细胞受体特异性方式重排为均匀的Valpha-Jalpha获得，其中 给药对象是具有MHC基因座的同种异体个体，其包含至少一个具有与NKT细胞基因型不同的基因座。 此外，本发明提供了一种人源细胞或源自所述细胞的NKT细胞，其中T细胞受体（TCR）基因的α链区域被重新排列成均匀的Valpha-Jalpha。 本发明的药剂和细胞库可用于预防和/或治疗癌症，感染，过敏性疾病或自身免疫性疾病。
-
公开(公告)号：US20110236362A1
公开(公告)日：2011-09-29
申请号：US13062453
申请日：2009-09-08
CPC分类号： A61K31/7036 , A61K35/12 , C12N5/0646 , C12N5/0696 , C12N2501/23 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/26 , C12N2501/42 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/11 , C12N2506/45
摘要： Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination.
摘要翻译： 提供衍生自体细胞如NKT细胞的iPS细胞，其具有T细胞抗原受体基因的α链区域以NKT细胞受体特异性方式重排为均匀的Vα-Jα，从iPS分化的NKT细胞 细胞，其制备方法以及使用从iPS细胞分化的细胞制备的免疫细胞治疗剂。 还提供了将具有重排为T细胞抗原受体基因的α-链区域的体细胞例如NKT细胞与NKT-TCR（NKT-iPS细胞）重排的TCRα的iPS细胞重排为均匀的Vα -Jα以NKT细胞受体特异性方式，具有核重编程因子，通过离体iPS细胞（iPS-NKT细胞）分化获得的分离的NKT细胞，产生CD4 / CD8-双重阳性NKT细胞的方法（DP-NKT 细胞）和来自NKT-iPS细胞的成熟NKT细胞，通过改变饲养细胞和/或细胞因子的组合，扩增iPS-NKT细胞的方法和包含用α-半乳糖基神经酰胺（α）活化的NKT细胞的NKT细胞细胞治疗剂 -GalCer）或iPS-NKT细胞和α-GalCer组合。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.018 秒)
